ELISA News and Research

RSS

BioGenes study documents insufficient sensitivity of ELISA-based generic HCP assay

BioGenes GmbH, a supplier of GMP-compliant immunoassays and antibodies, completed a study that documents the insufficient sensitivity of an ELISA-based generic host cell protein assay. The results confirm the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes.

12 May 2010

OriGene Technologies, ISB to create proteotypic PeptideAtlas and SRM/MRM mass spectrometry standard database

OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.

12 May 2010

Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement.

10 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

APiX View Detection Kits available for ultra-sensitive chromogenic detection of protein microarrays

Gentel Biosciences, a leader in proteomics discovery tools, today announced the availability of the APiX View Detection Kits for ultra-sensitive chromogenic detection of protein microarrays, including reverse phase protein such as SomaPlex arrays from Protein Biotechnologies.

17 Apr 2010

Serametrix announces commercial launch of serum test for measuring serum antibodies

Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments.

16 Apr 2010

IVAX Diagnostics signs two-year distribution agreement with Biomerica

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, and Biomerica, Inc., a global biomedical company, have signed a two-year agreement for the distribution of Biomerica's products in the U.S. and globally, with certain country and product exclusions.

13 Apr 2010

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company has completed enrollment of all subjects for its therapeutic cervical cancer vaccine (VGX-3100) phase I trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18, and is delivered via in vivo electroporation.

8 Apr 2010

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announces the availability of new Human multiplex biomarker panels for the quantification of seven biomarkers related to drug-induced vascular injury.

8 Apr 2010

IVAX Diagnostics reports net revenue of $4.5M for quarter ended December 31, 2009

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the fourth quarter and full year ended December 31, 2009.

31 Mar 2010

Researchers devise simple water test to check for herbicide clomazone

University of California, Davis, scientists are helping rice farmers in Uruguay stop polluting their waterways -- including drinking-water sources and a globally valuable nature reserve.

23 Mar 2010

OriGene Technologies to build TrueMAB monoclonal antibody collection with $16M Series B financing funds

OriGene Technologies, Inc., a leading gene-centric life sciences company, announced the completion of a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. OriGene's previous investors Morningside Venture Investments and President International Development Corp. (PIDC) also participated in this round. The proceeds from the funding will be used to continue to build OriGene's TrueMAB™ monoclonal antibody collection.

18 Mar 2010

China Sky One Medical's 2009 fourth-quarter total revenues up 15.0%

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced financial results for the fourth quarter and fiscal year ended December 31, 2009. The Company also announced its earnings guidance for full year 2010.

17 Mar 2010

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.

2 Mar 2010

Determining personal risk for genetic disorders essential

Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.

1 Mar 2010

New guidance document to prevent food allergies

For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.

19 Feb 2010

Gentel Biosciences launches integrated Proteomics Multi-System

Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing “scan-to-analysis” functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.

19 Feb 2010

SafeBridge Consultants validates improved hygiene air sampling and analytical method for naproxen sodium

SafeBridge® Consultants, Inc. headquartered in Mountain View, California announced today that its industrial hygiene analytical laboratory has recently validated an industrial hygiene air sampling and analytical method with improved analytical sensitivity for measurement of naproxen sodium on filters. SafeBridge now has a validated method that will detect as low as 20 picograms per filter in an air sample collected on appropriate media. This limit of detection is four (4) to five (5) times lower than methods available from other commercial laboratories.

11 Feb 2010

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

8 Feb 2010